Augustine Therapeutics NV
Latest round
- Series A
Last raised
- Feb 2025
Total raised
- $53M
Investors
- 12
About Augustine Therapeutics NV
Founded in 2019 in Leuven, Belgium, Augustine Therapeutics specializes in developing Histone Deacetylase 6 (HDAC6) inhibitors.Augustine Therapeutics specializes in the development of novel Histone Deacetylase 6 (HDAC6) inhibitors, targeting chronic conditions such as neuromuscular and neurodegenerative disorders. Their lead product, AGT-100216, is the first selective HDAC6 inhibitor aimed specifically at Charcot-Marie-Tooth Disease (CMT), designed to selectively inhibit HDAC6 while maintaining its beneficial functions.Augustine Therapeutics' revenue strategy relies on partnerships and collaborations for the development and commercialization of its HDAC6 inhibitors. Revenue generation is structured around partnership agreements with pharmaceutical companies, encompassing milestone payments and potential royalties upon product commercialization. The company plans to further develop this product while exploring market expansion into North America and Europe, aiming for greater geographical reach by leveraging new partnerships.
Who invested in Augustine Therapeutics NV
12 investors across 3 rounds
See all investors in Augustine Therapeutics NV
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Augustine Therapeutics NV
Who invested in Augustine Therapeutics NV?
Augustine Therapeutics NV has 12 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Augustine Therapeutics NV raised?
Augustine Therapeutics NV has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Augustine Therapeutics NV last raise money?
Augustine Therapeutics NV's most recent round on record is a Series A, in Feb 2025.
What does Augustine Therapeutics NV do?
Founded in 2019 in Leuven, Belgium, Augustine Therapeutics specializes in developing Histone Deacetylase 6 (HDAC6) inhibitors.
Where is Augustine Therapeutics NV headquartered?
Augustine Therapeutics NV is headquartered in Leuven, Belgium.
Which VCs invest in companies like Augustine Therapeutics NV?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Augustine Therapeutics NV's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Augustine Therapeutics NV? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.